There are three recognized criteria to evaluate the utility of a biomarker in cardiovascular medicine. A biomarker should be:

  • Measurable at a reasonable cost on short notice
  • Add new information to a clinical workup
  • Aid in the management of patients with cardiovascular disease

A biomarker in heart failure enables a clinician to identify underlying and possibly reversible causes of heart failure, confirms the presence or absence of heart failure syndrome, and estimates the severity of heart failure and the risk of disease progression. The method of judging a biomarker should be thorough, contemporary, rigorous, standardized and fair. The measurement of a biomarker should be easily achieved within a short period of time and provide acceptable accuracy. Its measurement should have defined biological variation and low analytical imprecision. It should reflect important pathological and physiological processes involved in the presence and progression of heart failure. It should also provide independently useful information relating to the diagnosis, prognosis, progression and therapy of the heart failure syndrome.

It must provide clinically useful information for caregivers, including physicians, nurses and others, and patients, to facilitate fast and reliable establishment or rejection of a diagnosis, a more accurate estimation of the prognosis and to inform more successful strategies for therapeutic interventions. The information from a biomarker should not repeat clinical information already available and must be in addition to information provided by other biomarkers.

Evaluating biomarkers is a complex process because heart failure is not the result of one single pathological or physiological disease. It is a syndrome that begins with cardiac volume or pressure overload characterized by a wide range of features, presentation and potential outcomes. Accordingly, biomarkers used in heart failure are commonly classified according to the processes with which they are involved. Because heart failure has a complementary and interactive nature, biomarkers related to the diagnosis combine well with markers from several categories.

Pathfast is an easy to use, bench-top chemiluminescent immunoassay analyzer providing affordable, core-lab quality results from whole blood samples in under 17 minutes. It can run six tests simultaneously and the results are unaffected by hemolysis. Pathfast ensures accurate results are available to the caregiver quickly, improving patient outcomes and overall cardiac care. Call us at 800-431-2123 or email tpucci@polymedco.com for additional information.

May 23rd, 2018

Posted In: Blog, Cardiac Biomarker

Tags: ,